Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder

References

• Major depression [Internet]. National Institute of Mental Health; 2019 February [cited 2019 Sept 15]. Available from: https://www.nimh.nih.gov/health/statistics/major-depression.shtml
   Google Scholar
• Depression and Other Common Mental Health Disorders: Global Health Estimates. World health organization [Internet]; 2017.[cited 2019 Sept 15]. Available from: http://www.who.int/mental_health/management/depression/prevalence_global_health_estimates/en/
   Google Scholar
• Rush AJ. Star-D: lessons learned and future implications. Depress Anxiety. 2011;28(7):521–524.
   PubMedGoogle Scholar
• Ionescu DF, Rosenbaum JF, Alpert JE. Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues Clin Neurosci. 2015;17(2):111–126.
   PubMed Web of Science ®Google Scholar
• Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry. 2006;67(Suppl 6):16–22.
   PubMed Web of Science ®Google Scholar
• Symbyax (fluoxetine hydrochloride and olanzapine) briefing materials. [Internet]. Food and Drug Administration; 2016 Apr 12 [cited 2019 Sept 15]. Available from: https://www.fda.gov/advisory-committees/pediatric-advisory-committee/symbyax-fluoxetine-hydrochloride-and-olanzapine-briefing-materials
   Google Scholar
• Zanos P, Moaddel R, Morris PJ, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev. 2018;70(3):621–660.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–864.
   PubMed Web of Science ®Google Scholar
• Iadarola ND, Niciu MJ, Richards EM, et al. Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Ther Adv Chronic Dis. 2015;6(3):97–114.
   PubMed Web of Science ®Google Scholar
• McEwen BS. Central effects of stress hormones in health and disease: understanding the protective and damaging effects of stress and stress mediators. Eur J Pharmacol. 2008;583(2–3):174–185.
   PubMed Web of Science ®Google Scholar
• McEwen BS, Eiland L, Hunter RG, et al. Stress and anxiety: structural plasticity and epigenetic regulation as a consequence of stress. Neuropharmacology. 2012;62(1):3–12.
   PubMed Web of Science ®Google Scholar
• Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959–964.
   PubMed Web of Science ®Google Scholar
• Li N, Liu RJ, Dwyer JM, et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry. 2011;69(8):754–761.
   PubMed Web of Science ®Google Scholar
• FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic [Internet]. Food and drug administration; 2019 Mar 5 [cited 2019 Sept 15]. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm632761.htm
   Google Scholar
• Committee for medicinal products for human use (CHMP) [Internet]. European Medicines Agency; 2018 Sept 7 [cited 2019 Sept 15]. Available from: https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-25-28-june-2018_en.pdf
   Google Scholar
• Domino EF. Taming the ketamine tiger. 1965. Anesthesiology. 2010;113(3):678–684.
   PubMed Web of Science ®Google Scholar
• Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–354.
   PubMed Web of Science ®Google Scholar
• Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67(8):793–802.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71(11):939–946.
   PubMed Web of Science ®Google Scholar
• Bobo WV, Vande Voort JL, Croarkin PE, et al. Ketamine for treatment-resistant unipolar and bipolar major depression: critical review and implications for clinical practice. Depress Anxiety. 2016;33(8):698–710.
   PubMed Web of Science ®Google Scholar
• Aan Het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67(2):139–145.
   PubMed Web of Science ®Google Scholar
• Shiroma PR, Albott CS, Johns B, et al. Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. Int J Neuropsychopharmacol. 2014;17(11):1805–1813.
   PubMed Web of Science ®Google Scholar
• Rasmussen KG, Lineberry TW, Galardy CW, et al. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol. 2013;27(5):444–450.
   PubMed Web of Science ®Google Scholar
• Arabzadeh S, Hakkikazazi E, Shahmansouri N, et al. Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial. J Affect Disord. 2018;235:236‐241.
   PubMed Web of Science ®Google Scholar
• Domany Y, Bleich-Cohen M, Tarrasch R, et al. Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study. Br J Psychiatry. 2019;214(1):20–26.
   PubMed Web of Science ®Google Scholar
• Chong C, Schug SA, Page-Sharp M, et al. Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: preliminary findings from a three-way randomized, crossover study. Clin Drug Investig. 2009;29(5):317–324.
   PubMed Web of Science ®Google Scholar
• Yanagihara Y, Ohtani M, Kariya S, et al. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos. 2003;24(1):37–43.
   PubMed Web of Science ®Google Scholar
• Li L, Vlisides PE. Ketamine: 50 years of modulating the mind. Front Hum Neurosci. 2016;10:612.
   PubMed Web of Science ®Google Scholar
• Lapidus KA, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014;76(12):970–976.
   PubMed Web of Science ®Google Scholar
• Oye I, Paulsen O, Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther. 1992;260(3):1209–1213.
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Leenders KL, Oye I, et al. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol. 1997;7(1):25–38.
   PubMed Web of Science ®Google Scholar
• Ihmsen H, Geisslinger G, Schüttler J. Stereoselective pharmacokinetics of ketamine: R(-)-ketamine inhibits the elimination of S(+)-ketamine. Clin Pharmacol Ther. 2001;70(5):431–438.
   PubMed Web of Science ®Google Scholar
• Zhang JC, Li SX, Hashimoto K. R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav. 2014;116:137–141.
   PubMed Web of Science ®Google Scholar
• Yang C, Shirayama Y, Zhang JC, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015;5:e632.
   PubMed Web of Science ®Google Scholar
• Fukumoto K, Toki H, Iijima M, et al. Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine. J Pharmacol Exp Ther. 2017;361(1):9–16.
   PubMed Web of Science ®Google Scholar
• Zanos P, Moaddel R, Morris PJ, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533(7604):481–486.
   PubMed Web of Science ®Google Scholar
• Zanos P, Gould TD. Intracellular signaling pathways involved in (S)- and (R)-ketamine antidepressant actions. Biol Psychiatry. 2018;83(1):2–4.
   PubMed Web of Science ®Google Scholar
• Singh JB, Fedgchin M, Daly E, et al. Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry. 2016;80(6):424–431.
   PubMed Web of Science ®Google Scholar
• Correia-Melo FS, Argolo FC, Araújo-de-Freitas L, et al. Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review. Neuropsychiatr Dis Treat. 2017;13:1627–1632.
   PubMed Web of Science ®Google Scholar
• Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018;75(2):139–148.
   PubMed Web of Science ®Google Scholar
• Canuso CM, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2018;175(7):620–630.
   PubMed Web of Science ®Google Scholar
• Fedgchin M, Trivedi M, Daly EJ, et al. Randomized, double-blind study of fixed-dosed intranasal esketamine plus oral antidepressant vs. active control in treatment-resistant depression. Poster session presented at: 9th Biennial Conference of the International Society for Affective Disorders (ISAD) and the Houston Mood Disorders Conference; 2018 Sept; Houston, TX.
   Google Scholar
• Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176(6):428–438.
   PubMed Web of Science ®Google Scholar
• Ochs-Ross R, Daly EJ, Zhang Y, et al. Efficacy and safety of intranasal esketamine plus an oral antidepressant in elderly patients with treatment-resistant depression. Biol Psychiatry. 2018;83(9):S391.
   Web of Science ®Google Scholar
• Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019 Jun 5;76:893.
   PubMed Web of Science ®Google Scholar
• Wajs E, Leah A, Morrison R, et al. Long-term safety of esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: SUSTAIN-2 phase study. Eur Neuropsychopharmacol. 2019;29:S44–S45.
   Google Scholar
• Food and Drug Administration. Psychopharmacologic drugs advisory committee (PDAC) and drug safety and risk management (DSaRM) advisory committee meeting: esketamine. 2019.
   Google Scholar
• Spravato (Esketamine) Label. 2019 food and drug administration [Internet]; 2019 May [cited 2019 Sept 15]. Available from: http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdf
   Google Scholar
• Morgan CJ, Curran HV. Independent scientific committee on drugs. Ketamine use: a review. Addiction. 2012 Jan;107(1):27–38. Epub 2011 Jul 22.
   PubMed Web of Science ®Google Scholar
• Singh I, Morgan C, Curran V, et al. Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight. Lancet Psychiatry. 2017;4(5):419–426.
   PubMed Web of Science ®Google Scholar
• NDA 211243 Esketamine treatment of treatment-resistant depression (TRD) [Internet]. Food and Drug Administration; [cited 2019 Sept 15]. Available from: https://www.fda.gov/media/121378/download
   Google Scholar
• Krystal JH, D’Souza DC, Mathalon D, et al. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl). 2003;169(3–4):215–233.
   PubMed Web of Science ®Google Scholar
• Morgan CJ, Curran HV. Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology (Berl). 2006;188(4):408–424.
   PubMed Web of Science ®Google Scholar
• Morgan CJ, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction. 2010;105(1):121–133.
   PubMed Web of Science ®Google Scholar
• Narendran R, Frankle WG, Keefe R, et al. Altered prefrontal dopaminergic function in chronic recreational ketamine users. Am J Psychiatry. 2005;162(12):2352–2359.
   PubMed Web of Science ®Google Scholar
• Perry EB Jr, Cramer JA, Cho HS, et al. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology (Berl). 2007;192(2):253–260.
   PubMed Web of Science ®Google Scholar
• Pal HR, Berry N, Kumar R, et al. Ketamine dependence. Anaesth Intensive Care. 2002;30(3):382–384.
   PubMed Web of Science ®Google Scholar
• Moore NN, Bostwick JM. Ketamine dependence in anesthesia providers. Psychosomatics. 1999;40(4):356–359.
   PubMed Web of Science ®Google Scholar
• Hurt PH, Ritchie EC. A case of ketamine dependence. Am J Psychiatry. 1994;151(5):779.
   PubMed Web of Science ®Google Scholar
• Pfenninger EG, Durieux ME, Himmelseher S. Cognitive impairment after small-dose ketamine isomers in comparison to equianalgesic racemic ketamine in human volunteers. Anesthesiology. 2002;96(2):357–366.
   PubMed Web of Science ®Google Scholar
• Sinner B, Graf BM. Ketamine. Handb Exp Pharmacol. 2008;182:313–333.
   PubMedGoogle Scholar
• Morrison RL, Fedgchin M, Singh J, et al. Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study. Psychopharmacology (Berl). 2018;235(4):1107–1119.
   PubMed Web of Science ®Google Scholar
• Paul R, Schaaff N, Padberg F, et al. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. World J Biol Psychiatry. 2009;10(3):241–244.
   PubMed Web of Science ®Google Scholar
• Correia-Melo FS, Leal GC, Carvalho MS, et al. Comparative study of esketamine and racemic ketamine in treatment-resistant depression: protocol for a non-inferiority clinical trial. Medicine (Baltimore). 2018;97(38):e12414.
   PubMed Web of Science ®Google Scholar
• Janssen Research & Development, LLC. Crossover study to evaluate the abuse potential of intranasal esketamine compared to racemic intravenous ketamine in nondependent, recreational drug users. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2019 Aug 15] Available from: https://clinicaltrials.gov/ct2/show/NCT02682225 NLM Identifier: NCT02682225
   Google Scholar
• Schatzberg AF. A word to the wise about intranasal esketamine. Am J Psychiatry. 2019;176(6):422–424.
   PubMed Web of Science ®Google Scholar
• Henkin RI. Intranasal delivery to the brain. Nat Biotechnol. 2011;29(6):480.
   PubMed Web of Science ®Google Scholar
• Quintana DS, Steen NE, Andreassen OA. The promise of intranasal esketamine as a novel and effective antidepressant. JAMA Psychiatry. 2018;75(2):123–124.
   PubMed Web of Science ®Google Scholar
• Singh JB, Fedgchin M, Daly EJ, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173(8):816–826.
   PubMed Web of Science ®Google Scholar
• Ionescu DF, Bentley KH, Eikermann M, et al. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial. J Affect Disord. 2019;243:516–524.
   PubMed Web of Science ®Google Scholar